Triton 3 Patient Summary
TRITON3 Clinical Trial
This trial is for patients with prostate cancer where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of tumors that are BRCA1, BRCA2, or ATM genetic mutations or alterations.
This study will determine how patients with metastatic castration resistant prostate cancer and evidence of certain genetic mutations respond to treatment with the investigational agent rucaparib. Participants in this study will be randomly selected to receive rucaparib or an FDA approved therapy, including Zytiga (abiraterone), enzalutamide (xtandi), or docetaxel (taxotere).
Genetic mutations or alterations (BRCA1, BRCA2, ATM and others) can be detected in men with metastatic castration resistant prostate cancer by performing tumor gene sequencing on tissue samples from previous prostate surgery or biopsy samples. Genetic mutations or alterations can also be detected in blood.
Possible Patient Benefits: Rucaparib will slow the spread (progression) of prostate cancer better than abiraterone,enzalutamide or docetaxel.
Possible Patient Risks: Rucaparib will work no better than the current standard of care which is abiraterone, enzalutamide, or docetaxel. Side effects following use of rucaparib, abiraterone. Enzalutamide, or docetaxel are also possible.
Study Start Date: January 2017
Estimated Primary Completion Date: February 2022
Estimated Study Completion Date: April 2022
Clovis Contact: Clovis Oncology Clinical Trial Navigation Service